- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07305428
Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study
Hepatocellular carcinoma (HCC) is one of the commonest cancers worldwide and ranks the third on the incidence of cancer-related death. There are more than 500000 new cases diagnosed annually worldwide. The incidence and prevalence of HCC are on rising trend with the majority of the disease burden is in Asia where viral hepatitis B is endemic. Surgical resection, radiofrequency ablation (RFA) and liver transplantation (LT) represent the only chance of cure for HCC patients. Despite more aggressive surgical approach has been adopted in most Asian countries, yet curative intervention remains only amendable in 30% of patients. Most patients are diagnosed with intermediate or advanced stage diseases; the long-term cure rate is only 0-10%. Hence, every effort has been made in an attempt to convert inoperable HCC into operable disease (i.e. downstaging) in order to improve the chance of survival of these patients. The current study, to current knowledge, will be the first study in the field to deploy a novel treatment strategy to deploy both immunotherapy and stereotactic beamed radiotherapy to induce tumor shrinkage rendering it become operable cancer.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Albert Chan
- Phone Number: +852 2255 6646
- Email: hbptrial@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Queen Mary Hospital
-
Principal Investigator:
- Albert Chan
-
Contact:
- Albert Chan
- Phone Number: +852 2255 6646
- Email: hbptrial@hku.hk
-
Sub-Investigator:
- Chi Leung Chiang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of HCC is made according to American Association for the Study of Liver Diseases (AASLD) practice guideline 2010: patients with cirrhosis of any etiology and patients with chronic hepatitis B (HBV) who may not have fully developed cirrhosis, the presence of liver nodule >1cm and demonstrated in a single contrast enhanced dynamic imaging [either computed tomography (CT) or magnetic resonance imaging (MRI)] of intense arterial uptake and "washout" in portal venous and delayed phases.
- Tumor size 5-25 cm or number of lesions ≤3 or segmental portal vein involvement
- Age: 18-80 years old
- Child Pugh liver function class A-B7
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
-
Prior invasive malignancy
-
Prior radiotherapy to the region of liver or selective internal radiotherapy
-
Severe, active co-morbidity
-
Presence of extra-hepatic metastases (M1)
-
Main portal vein or inferior vena cava (IVC) thrombosis or involvement
-
Presence of ascites or encephalopathy
-
Contraindicated of SBRT:
- Any one hepatocellular carcinoma > 15 cm
- Total maximal sum of hepatocellular carcinoma > 25 cm
- More than 3 discrete hepatic nodule
- Direct tumor extension into the stomach, duodenum, small bowel, large bowel, common or main branch of biliary tree
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Stereotactic Body Radiation Therapy followed by Immunotherapy
The intervention will be done with Stereotactic Body Radiation Therapy and followed by Immunotherapy |
Stereotactic Body Radiation Therapy is a type of external radiation therapy that uses special equipment to position the patient and precisely deliver radiation to a tumor. Drugs for immunotherapy will be suggested and decided by doctors from Department of Clinical Oncology. The therapy will last for 2 years unless it is no longer helping the disease, or unacceptable toxicity, or until the disease is amendable to surgery.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
rate of successive tumour downstaging
Time Frame: at the time point of receiving surgery
|
show how many patients will be downstaged by receiving surgery |
at the time point of receiving surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Digestive System Neoplasms
- Digestive System Diseases
- Liver Diseases
- Neoplasms, Glandular and Epithelial
- Adenocarcinoma
- Liver Neoplasms
- Carcinoma
- Carcinoma, Hepatocellular
- Investigative Techniques
- Therapeutics
- Surgical Procedures, Operative
- Radiotherapy
- Stereotaxic Techniques
- Neurosurgical Procedures
- Biological Therapy
- Immunomodulation
- Radiosurgery
- Immunotherapy
Other Study ID Numbers
- UW19-286
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.